News

6.7.2021
Press Release

TOPADUR Pharma AG announces completion of TOP-N53 First-in-Man Study

TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.

Read more
1.7.2021
Press Release

TOPADUR submits an Orphan Drug Designation application for TOP-N53

TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.

Read more
27.5.2021
News

Innosuisse innovation project starting May 2021

TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.

Read more
10.11.2020
Press Release

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

Read more
27.10.2020
News

Scientific Publication in Chimia

TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.

Read more
8.10.2020
News

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.

Read more

Media Contact

Chief Project Officer & Communications
TOPADUR Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
paola.atzei@topadur.com+41 44 755 44 63